Chemistry:Etavopivat
From HandWiki
Etavopivat is an investigational new drug that is being evaluated by FORMA Therapeutics for the treatment of sickle cell disease and thalassemia. It is an allosteric activator of the erythrocyte pyruvate kinase R (PKR) enzyme.[1][2][3]
Clinical trials
Etavopivat is in phase 3 clinical trials for sickle cell disease and thalassemia.[4]
References
- ↑ "Etavopivat - FORMA Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800053945.
- ↑ "Erythrocyte pyruvate kinase activation in red cell disorders". Current Opinion in Hematology 30 (3): 93–98. May 2023. doi:10.1097/MOH.0000000000000758. PMID 36853806.
- ↑ "Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease". Hemoglobin: 1–13. June 2026. doi:10.1080/03630269.2026.2682386. PMID 42261266.
- ↑ Clinical trial number NCT06609226 for "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia" at ClinicalTrials.gov
 |  |
